GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Total Current Assets

VERV (Verve Therapeutics) Total Current Assets : $542.75 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Verve Therapeutics's total current assets for the quarter that ended in Dec. 2024 was $542.75 Mil.


Verve Therapeutics Total Current Assets Historical Data

The historical data trend for Verve Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics Total Current Assets Chart

Verve Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial 73.97 367.13 563.16 637.95 542.75

Verve Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 637.95 620.33 590.89 556.46 542.75

Verve Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Verve Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Verve Therapeutics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Verve Therapeutics  (NAS:VERV) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Verve Therapeutics's Liquidation Value for the quarter that ended in Dec. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=524.281-153.992+0.75 * 0+0.5 * 0
=370.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verve Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Verve Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Executives
Allison Dorval officer: Chief Financial Officer C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Andrew D. Ashe officer: See Remarks C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Joan Nickerson officer: Chief Administrative Officer C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Krishna Yeshwant director, 10 percent owner C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Fred T. Fiedorek officer: Chief Medical Officer 55 BALDWIN LANE, PRINCETON NJ 08540
Andrew Bellinger officer: Chief Scientific Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. other: Member of 10% Group 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan director, 10 percent owner, officer: Chief Executive Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman director, 10 percent owner DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129